Vedolizumab for subcutaneous injection in now indicated for maintenance therapy following IV induction in both Crohn disease and ulcerative colitis.
Your daily dose of the clinical news you may have missed.
Bempedoic acid became the first nonstatin LDL-C lowering medication indicated to reduce CV risk in both primary and secondary prevention. Nissen explains how.
The additional indication for benralizumab was supported by data from the phase 3 TATE trial.
The Low EF AI is designed to detect low ejection fraction in 15 seconds during a primary care exam.
Your daily dose of the clinical news you may have missed.
Your daily dose of the clinical news you may have missed.
Specifically, the topical analgesics, available over the counter, may contain higher than labeled concentrations of lidocaine, according to the agency.
The FDA approved the oral medication to treat anemia in adult patients with chronic kidney disease on dialysis for at least 3 months.
For the first time, 2 drugs recommended as first line treatment for PAH are combined in a single oral once-daily therapy, which could reduced burden of care.